摘要
目的观察来氟米特联合甲氨蝶呤治疗中老年类风湿关节炎的安全性及预后。方法选取收治符合纳入标准的类风湿关节炎患者90例,按随机数字表法分为对照组与观察组,每组45例。对照组患者给予甲氨蝶呤治疗,观察组患者在对照组的基础上加用来氟米特治疗,两组患者治疗疗程均为12个月。比较两组患者干预前后临床症状、用药毒副作用发生率、不良反应发生率。结果干预后,两组患者晨僵时间、握力、关节压痛数、关节肿胀数均明显改善,与干预前比较差异有统计学意义(P <0.05),且观察组患者改善程度明显优于对照组,差异有统计学意义(P <0.05);观察组药物干预后毒副作用发生率为6.6%,对照组为8.8%,差异无统计学意义(P> 0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P <0.05)。结论使用来氟米特联合甲氨蝶呤治疗中老年类风湿关节炎更为安全有效,且能降低不良反应发生率,改善患者预后,可作为类风湿关节炎治疗方案选择。
Objective To observe the safety and prognosis of leflunomide combined with methotrexate in the treatment of middle-aged and elderly patients with rheumatoid arthritis. Methods Ninety patients with rheumatoid arthritis admitted to our hospital were divided into control group and observation group according to random number table method, 45 cases in each group. The control group were treated with methotrexate. The observation group were treated with leflunomide on the basis of the control group, both with 12 months treatment course. The clinical symptoms, the incidence of toxic and side effects and the incidence of adverse reactions before and after intervention were compared between the two groups. Results After intervention, morning stiffness time, grip strength, joint tenderness and joint swelling were significantly improved in both groups, with significant difference compared with before intervention(P< 0.05).After intervention, the incidence of toxic and side effects was 6.6% in the observation group and 8.8% in the control group. There was no significant difference between the two groups(P > 0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P < 0.05).Conclusion Leflunomide combined with methotrexate is safe and effective in the treatment of middle-aged and elderly patients with rheumatoid arthritis. It can reduce the incidence of adverse reactions and improve the prognosis of patients. It can be used as a treatment option for rheumatoid arthritis.
作者
谭玉梅
TAN Yu-mei(Beihai city people's hospital,Beihai,Guangxi 536000,China)
出处
《中国处方药》
2020年第4期82-84,共3页
Journal of China Prescription Drug
